RLT-PSMA
RLT-PSMA
Radioligand therapy prostate-specific membrane antigen
Advertisement
Emily MenendezProstate Cancer | March 16, 2023
The new indication will improve access to imaging for approximately 32,000 candidates for radioligand therapy in the US.
Read More
Scott Tagawa, MD, MS, FACPRLT-PSMA | February 22, 2023
Scott Tagawa, MD, MS, FACP, shares what needs to happen for radionuclide therapy to make its way into the community setting.
Scott Tagawa, MD, MS, FACPRLT-PSMA | February 22, 2023
Scott Tagawa, MD, MS, FACP, highlights what clinicians must know prior to recommending Lutetium-177–PSMA-617 to patients.
Gary Ulaner, MD, PhD, FACNMRLT-PSMA | January 24, 2023
Dr. Ulaner highlights the line(s) of therapy in which novel RLT-PSMA agents are being developed.
Gary Ulaner, MD, PhD, FACNMRLT-PSMA | January 24, 2023
Dr. Ulaner explains the data that led to the FDA approval of 177Lu-PSMA-617 and the safety profile of this drug.
Zachary BessetteRLT-PSMA | January 23, 2023
Moffitt Cancer Center developed the first PRO measure for patients receiving RNT to guide treatment and improve QoC.
Emily MenendezRLT-PSMA | January 12, 2023
While PSMA-RLT is typically used during later disease stages, patients in earlier disease stages may benefit as well.
Zachary BessetteRLT-PSMA | January 4, 2023
Implementing a genetic testing model for prostate cancer patients can improve detection rates for actionable mutations.
Robert DillardRLT-PSMA | December 21, 2022
A study sought to assess organoids and short-term ex vivo cultures of prostate cancer.
Robert DillardRLT-PSMA | December 21, 2022
Researchers developed the first validated risk model for discerning personalized prostate cancer risks.
Robert DillardRLT-PSMA | December 21, 2022
A risk score can predict prostate cancer in men of African ancestry.
Robert DillardRLT-PSMA | December 21, 2022
A greater family history of prostate cancer is associated with a lower risk of mortality.
Jacqueline T. Brown, MDRLT-PSMA | December 21, 2022
Dr. Jacqueline Brown talks about current challenges and advances in phenotypic precision medicine and treatment strategies.
Emily MenendezRLT-PSMA | December 20, 2022
Researchers analyzed 18F-PSMA-1007 PET/CT radiomics for their efficacy in determining tumor malignancy in prostate cancer.
Emily MenendezRLT-PSMA | December 20, 2022
An auto-segmentation model for PSMA PET-delineated tubarial glands has been recently examined.
Emily MenendezRLT-PSMA | December 20, 2022
A recent study analyzed the efficacy of 68Ga-PSMA PET/CT in patients with a history of prostate cancer who have BCR.
Emily MenendezRLT-PSMA | December 20, 2022
The single-center, single-arm phase 1/2 AlphaBet trial will evaluate radium-223 & [177Lu]Lu-PSMA-I&T in patients with mCRPC.
Jacqueline T. Brown, MDRLT-PSMA | December 20, 2022
Dr. Jacqueline Brown talks about current developments in phenotypic precision medicine for prostate cancer.
Jacqueline T. Brown, MDRLT-PSMA | December 19, 2022
Jacqueline T. Brown, MD talks about the current state of phenotypic precision medicine for advanced prostate cancer.
Emily MenendezRLT-PSMA | November 29, 2022
The effectiveness of PSMA PET was compared with conventional imaging & liver biopsy, and a radiomic model was also evaluated.
Advertisement
Advertisement
Advertisement